Single Patient IND
Melphalan
FDA Approved
Risks Associated with Melphalan
Frequent (Between a 10-50% chance that this will happen)
• Sores in the mouth and esophagus, which may be painful and cause difficulty swallowing.
Occasional (Between a 1-10% chance that this will happen)
• A low number of white blood cells may increase the risk of infection. It may become life-threatening. Symptoms of infection may include fever, pain, redness, and/or difficulty breathing.
• Low number of red blood cells that can causes tiredness and shortness of breath. May require a blood transfusion.
• Allergic reaction that may include a rash, hives, fever, difficulty breathing, and low blood pressure. Although usually reversible with treatment, it can be severe or life threatening.
• Kidney failure, which is when both of your kidneys fail and your body holds fluid which can be serious or life threatening. Your blood pressure rises and harmful wastes build up in your body. You may experience fatigue, nausea, and loss of appetite. When this happens, you need treatment to replace the work of your failed kidneys such as dialysis.
• Scarring of the lungs that can affect your ability to breath and may make you short of breath. This may be serious or life threatening.
• Low number of platelets, which may cause bleeding and bruising. Bleeding may be serious or life threatening and may required a blood transfusion.
• Hepatitis which may cause yellow eyes and skin, tiredness
• A second cancer related to the treatment of your first cancer. This usually occurs years after treatment for the first cancer.
Rare (Less than a 1% chance that this will happen)
• Sudden, unexpected stopping of the heart. This is serious and life-threatening.
-----------------------
DANA-FARBER / HARVARD CANCER CENTER
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- title gastroesophageal reflux disease
- motility disorders of oesophagus
- treatment pharma lecture
- duty to assist development required
- single patient ind
- 4 114 veterans affairs
- chapter 23 diseases of the digestive system
- gi—diseases of the esophagus
- m29 1 part 5 e
- sample sti standing delegation orders for nurse clinicians
Related searches
- blackrock equity ind non led m
- blackrock s p 500 ind vi
- gadsden ind school district
- blackrock equity ind nl m
- ind submission requirements fda
- ind submission checklist
- lotto quick draw ind for 1 year
- ind document level checklist
- ind application checklist
- fda ind checklist
- ind private school baltimore md
- fda ind application requirements